Nicolas Palaskas
Overview
Explore the profile of Nicolas Palaskas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jensen G, Wang X, Kuempel J, Palaskas N, Chen Z, Yu W, et al.
Am J Physiol Heart Circ Physiol
. 2025 Feb;
328(4):H734-H751.
PMID: 39925096
The most fatal side effect associated with revolutionary immune checkpoint inhibitor (ICI) cancer therapies is myocarditis, a rare and devastating complication with a mortality rate approaching 40%. This review comprehensively...
2.
Jensen G, Wang X, Kuempel J, Chen Z, Yu W, Palaskas N, et al.
J Mol Cell Cardiol Plus
. 2025 Jan;
10.
PMID: 39742339
Immune checkpoint inhibitor-associated myocarditis is the most lethal side effect of immune checkpoint blockade. Myocarditis leads to persistently increased mortality and lacks effective treatments. The development of patient-relevant disease models...
3.
Bloom M, Vo J, Rodgers J, Ferrari A, Nohria A, Deswal A, et al.
J Card Fail
. 2024 Oct;
31(2):415-455.
PMID: 39419165
Heart failure and cancer remain 2 of the leading causes of morbidity and mortality, and the 2 disease entities are linked in a complex manner. Patients with cancer are at...
4.
Bloom M, Vo J, Rodgers J, Ferrari A, Nohria A, Deswal A, et al.
J Card Fail
. 2024 Oct;
31(2):456-463.
PMID: 39414560
No abstract available.
5.
Irizarry-Caro J, Song J, Miller C, Desai S, Going J, Fossas-Espinosa J, et al.
Cardiovasc Drugs Ther
. 2024 Jan;
PMID: 38224416
Purpose: The purpose of this study was to evaluate safety and cardiovascular outcomes as well as overall survival of cancer patients with concomitant heart failure (HF) treated with midodrine for...
6.
Potter A, Hulsurkar M, Wu L, Narasimhan B, Karimzad K, Koutroumpakis E, et al.
JACC Clin Electrophysiol
. 2023 Apr;
9(4):591-602.
PMID: 37100538
Recent advances have significantly expanded the options of available therapeutics for cancer treatment, including novel targeted cancer therapies. Within this broad category of targeted therapies is the class of kinase...
7.
Koutroumpakis E, Niku A, Black C, Ali A, Sadaf H, Song J, et al.
Front Cardiovasc Med
. 2023 Feb;
9:1073804.
PMID: 36762300
Introduction: This study examined the role of echocardiographic and cardiac histomorphology parameters in predicting mortality in patients with cardiac AL amyloidosis. Methods: Patients with endomyocardial biopsy-proven cardiac AL amyloidosis treated...
8.
Safdar A, Ahmed T, Liu V, Addoumieh A, Agha A, Giza D, et al.
Front Cardiovasc Med
. 2022 Nov;
9:1019284.
PMID: 36386379
Background: Takotsubo syndrome (TTS) occurs more frequently in cancer patients than in the general population, but the effect of specific TTS triggers on outcomes in cancer patients is not well...
9.
Kim J, Monlezun D, Park J, Chauhan S, Balanescu D, Koutroumpakis E, et al.
Resuscitation
. 2022 Aug;
179:43-49.
PMID: 35933056
Background: Cancer patients are less likely to undergo percutaneous coronary intervention (PCI) after cardiac arrest, although they demonstrate improved mortality benefit from the procedure. We produced the largest nationally representative...
10.
Kim J, Dayah T, Javaid A, Monlezun D, Balanescu D, Donisan T, et al.
Medicina (Kaunas)
. 2022 Jul;
58(7).
PMID: 35888603
Background and Objectives: Cancer and coronary artery disease (CAD) often coexist. Compared to quantitative coronary angiography (QCA), fractional flow reserve (FFR) has emerged as a more reliable method of identifying...